The Regev Laboratory infers cellular and tissue circuits by combining perturbation, profiling, and computational inference. They both develop new experimental and computational methods for this task, and apply them extensively in primary mammalian cells, especially from the immune system, and in mammalian tissues, especially cancers, epithelia such as the gut and lung, and the brain. The Regev Laboratory has been a leading pioneer of single cell genomics; they have invented, developed, and applied many of the experimental and computational methods in the field, and they continue to do so, including for spatial genomics and for pooled screens with high content, single cell readout in vitro and in vivo.

Dr. Regev currently serves as head of Genentech research and early development (gRED).